Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial - The Lancet
Acalabrutinib - wikidoc
In-Vivo Demonstration of Enhanced Bioavailability of Acalabrutinib ASD Tablets
Calquence Full Prescribing Information, Dosage & Side Effects | MIMS Hong Kong
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients | Haematologica
Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile | Journal of Pharmacology and Experimental Therapeutics
astrazeneca Acalabrutinib Calquence 100Mg, 2*6 Capsules at Rs 160000/box in Ahmedabad
Acalabrutinib (Calquence) - Oncology Nurse Advisor
Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma | PLOS ONE
Acalabrutinib: Nursing Considerations for Use in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | ONS
Pharmacokinetic data. Plasma levels of acalabrutinib were measured at... | Download Scientific Diagram
Determining drug dose in the era of targeted therapies: playing it (un)safe? | Blood Cancer Journal
Drug International Limited
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study - The Lancet Oncology
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia | NEJM
Acalabrutinib in treatment-naive chronic lymphocytic leukemia - ScienceDirect
Incorporating acalabrutinib, a selective next‐generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies - Danilov - 2021 - British Journal of Haematology - Wiley Online Library
Reduced dosing of acalabrutinib: I recently... - CLL Support
Acalabrutinib (Calquence®) + Obinutuzumab (Gazyva®) for CLL | ChemoExperts
Acalabrutinib (Calquence) - Oncology Nurse Advisor
